ATXN3 and Spinocerebellar ataxia type 3: To our best knowledge, this is the first study that reported a promising therapeutic effect of SCA3/MJD treatment by delivering miRNAs via engineered exosomes and the first that evaluated the in vivo effect of miR-25 in SCA3/MJD.